论文部分内容阅读
目的探讨分析胸腺五肽联合抗结核药物对肺结核患者免疫功能及临床疗效的影响。方法采用前瞻性病例对照研究方法。选取肺结核患者40例为对照组,常规抗结核药物治疗。同期入院患者40例为试验组,给予胸腺五肽与常规抗结核药物联合治疗。分别于治疗6个月时,比较两组患者临床疗效、肺功能改善情况及外周血T淋巴细胞亚群水平。结果两组患者均完成治疗。试验组治疗6个月时,痰菌转阴率为75.0%(30/40),病灶吸收率为77.5%(31/40),空洞闭合率为80.0%(32/40)。而对照组则分别为50.0%(20/40)、52.5%(21/40)、52.5%(21/40)。试验组病灶吸收率、痰菌转阴率及空洞闭合率均优于对照组。治疗后两组患者CD4+CD25+显著下降,CD4+、CD4+/CD8+水平均显著升高,但试验组改善幅度优于对照组);而CD8+水平轻度下降。试验组治疗后肺功能指标优于对照组。结论对于肺结核患者,采用胸腺五肽联合抗结核药物可有效提高临床疗效,改善肺功能及免疫功能。
Objective To investigate the effects of thymopentin combined with anti-tuberculosis drugs on immune function and clinical efficacy in patients with pulmonary tuberculosis. Methods A prospective case-control study was used. 40 cases of tuberculosis patients were selected as the control group, conventional anti-TB drug treatment. In the same period 40 patients were admitted to the test group, given thymopentin combined with conventional anti-TB drugs. At 6 months of treatment, the clinical efficacy, the improvement of pulmonary function and the level of T lymphocyte subsets in peripheral blood were compared between the two groups. Results Both groups completed the treatment. At 6 months, the rate of sputum negative conversion was 75.0% (30/40) in the experimental group, and the rate of focal lesion was 77.5% (31/40). The void closure rate was 80.0% (32/40). While those in the control group were 50.0% (20/40), 52.5% (21/40) and 52.5% (21/40), respectively. The absorption rate of the lesion in the experimental group, the negative conversion rate of sputum bacteria and the void closure rate were better than those in the control group. After treatment, CD4 + CD25 + and CD4 +, CD4 + / CD8 + were significantly decreased in both groups, but the improvement in the experimental group was better than that in the control group); while the level of CD8 + decreased slightly. The experimental group after treatment lung function index better than the control group. Conclusion For patients with pulmonary tuberculosis, the combination of thymopentin and anti-TB drugs can effectively improve the clinical efficacy and improve lung function and immune function.